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Abstract
Background: Hyponatremia is the most common electrolyte disorder in clinical practice, and evidence to date indicates that
severe hyponatremia is associated with increased morbidity and mortality. The aim of our study was to perform a meta-
analysis that included the published studies that compared mortality rates in subjects with or without hyponatremia of any
degree.
Methods and Findings: An extensive Medline, Embase and Cochrane search was performed to retrieve the studies
published up to October 1st 2012, using the following words: ‘‘hyponatremia’’ and ‘‘mortality’’. Eighty-one studies satisfied
inclusion criteria encompassing a total of 850222 patients, of whom 17.4% were hyponatremic. The identification of relevant
abstracts, the selection of studies and the subsequent data extraction were performed independently by two of the authors,
and conflicts resolved by a third investigator. Across all 81 studies, hyponatremia was significantly associated with an
increased risk of overall mortality (RR = 2.60[2.31–2.93]). Hyponatremia was also associated with an increased risk of
mortality in patients with myocardial infarction (RR = 2.83[2.23–3.58]), heart failure (RR = 2.47[2.09–2.92]), cirrhosis
(RR = 3.34[1.91–5.83]), pulmonary infections (RR = 2.49[1.44–4.30]), mixed diseases (RR = 2.59[1.97–3.40]), and in hospitalized
patients (RR = 2.48[2.09–2.95]). A mean difference of serum [Na+] of 4.8 mmol/L was found in subjects who died compared
to survivors (130.165.6 vs 134.965.1 mmol/L). A meta-regression analysis showed that the hyponatremia-related risk of
overall mortality was inversely correlated with serum [Na+]. This association was confirmed in a multiple regression model
after adjusting for age, gender, and diabetes mellitus as an associated morbidity.
Conclusions: This meta-analysis shows for the first time that even a moderate serum [Na+] decrease is associated with an
increased risk of mortality in commonly observed clinical conditions across large numbers of patients.
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Introduction
Hyponatremia, defined as a serum sodium concentration
([Na+]) ,136 mmol/L, is the most common electrolyte disorder
encountered in clinical practice [1]. The most common cause of
hypotonic or dilutional hyponatremia is the syndrome of
inappropriate antidiuresis (SIAD). Mild hyponatremia (serum
[Na+] 130–135 mmol/L) has been estimated to occur in about 15–
30% of hospitalized patients, whereas the prevalence of moderate
to severe hyponatremia (serum [Na+] ,130) is as high as 7%
among in-hospital patients [2].
Hyponatremia represents a serious health problem with
significant associated morbidity and mortality. Acute severe
hyponatremia is a medical emergency accompanied by severe
neurological symptoms due to cerebral edema and can be lethal if
not recognized and appropriately treated [3]. The correction of
hyponatremia may per se represent a risk and a rare but potentially
lethal complication, i.e. the osmotic demyelination syndrome, may
be the result of an overly rapid correction [4]. In contrast, mild
chronic hyponatremia has traditionally been considered as an
asymptomatic or mildly symptomatic condition. However, recent
reports indicated that even mild chronic hyponatremia can have
long-term adverse effects, such as deficits in gait and attention [5],
falls [5], bone loss and fractures [6–9], especially in the elderly.
More recently, chronic hyponatremia has been shown to
exacerbate multiple manifestation of senescence in aged rats,
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including senile osteoporosis, sarcopenia, cardiac fibrosis, and
hypogonadism [10].
The association between hyponatremia and in-hospital mortal-
ity has been demonstrated in numerous studies. For instance, a
large cohort study, which included all adult hospitalizations
(n = 53236) at an academic medical center between 2000–2007,
demonstrated that even mild hyponatremia was associated with
increased in-hospital mortality, and that the risk of death was
increased by 2.3% for each 1 mmol/L decline of serum [Na+]
[11].
Hyponatremia has been generally associated with an increased
mortality in different conditions such as pneumonia [12], heart
failure [13], acute myocardial infarction [14], cirrhosis [15],
cancer [14], in the elderly [16], and in intensive care patients [17].
However, whether hyponatremia is an independent risk factor for
death or is simply associated with an underlying severe condition
that is the cause of death remains to be elucidated [4,18].
Furthermore, there is the possibility that hyponatremia indirectly
contributes to mortality by causing organ dysfunction, such as for
example bone loss and fractures which are associated with
significant mortality in the elderly. Recently, a meta-analysis that
included 22 observational studies and randomized controlled trials
published to the end of 2008, that was limited to patients with
heart failure, indicated that hyponatremia is a powerful predictor
of mortality in these patients regardless of ejection fraction [19].
However, no meta-analysis on the relationship between hypona-
tremia and mortality has addressed other pathological conditions
to date.
The aim of this study was to perform a meta-analysis, which
included the studies that compared the mortality rate in subjects
with or without hyponatremia, in order to verify whether
hyponatremia represents a risk factor for mortality, independently
of other confounding factors.
Methods
A meta-analysis was performed including studies comparing
mortality rate in subjects with or without hyponatremia. An
extensive Medline, Embase, and Cochrane search was
performed including the following words: hyponatremia and
mortality. The search up to October 1st 2012 was restricted to
English-language articles and studies of human participants.
The identification of relevant abstracts, the selection of studies
based on the criteria described above, and the subsequent data
extraction were performed independently by two of the authors
(G.P., C.G.), and conflicts resolved by a third investigator
(G.C). Full-text articles and meeting abstracts were included.
The quality of studies was assessed using the Cochrane criteria
[20].
Statistical analysis
Heterogeneity was assessed using the I2 statistics for overall
mortality rate. Considering that heterogeneity could not be
excluded (I2 = 92.8%), relative risk of mortality between subjects
with or without hyponatremia, was calculated using both a
random and fixed effect model. For a more conservative approach,
results of random effect models were presented. A meta-regression
analysis was performed to test the effect of serum [Na+] threshold
selected in the different studies on overall mortality rate levels. In
addition, a linear regression analysis model, weighing each study
for the number of subjects enrolled, was performed to verify the
independent effect of hyponatremia on mortality after the
adjustment for age, gender and diabetes mellitus as an associated
morbidity. It was not possible to include other co-morbidities
because there were not enough data to be collected and analyzed
from the selected literature. Finally, sensitivity analyses was
performed considering only larger studies (including $1000
subjects) or those reporting the prevalence of diabetes mellitus.
In addition, mean baseline serum [Na+] in subjects who eventually
died or not at follow up were meta-analyzed using a random effect
model.
Relative risks (RRs) with 95% CIs were calculated using
Comprehensive Meta-analysis Version 2, Biostat, (Englewood, NJ,
USA). Logistic multivariate analysis was performed on SPSS
(Statistical Package for the Social Sciences; Chicago, USA) for
Windows 20.1.
Results
Out of 718 retrieved articles, 637 articles were excluded for
different reasons. The flow of the meta-analysis is summarized in
Figure 1, and the characteristics of the trials included in the meta-
analysis are summarized in Table 1 (see references 3,11–12,16–18,
21–95). Among the 81 selected studies, 7, 13, 8, 5 studies evaluated
the effect of hyponatremia on overall mortality rate in subjects
with myocardial infarction, heart failure (HF), cirrhosis and
pulmonary infections, respectively. In addition, another 26 studies
reported data on the effect of hyponatremia on overall mortality
for combined mixed diseases, which could not be grouped
separately (see Table 1). Finally, 14 studies retrospectively
investigated the effect of hyponatremia on overall mortality in
hospitalized series of subjects. In these studies, a major diagnosis
was not specified.
The mean6SD serum [Na+] in dead or alive individuals was
specified in 3 of the aforementioned studies and in a further 8
studies enrolling patients with HF (n = 2), cirrhosis (n = 1),
pulmonary infection (n = 2) or mixed disease (n = 3), respectively
(Table 1).
Overall 850222 patients and 147948 hyponatremic subjects
were included in the meta-analysis. Hyponatremia was defined
according to varying cut-off definitions in the included studies
(Table 1). The Begg-adjusted rank correlation test, calculated on
the basis of overall mortality rate for hyponatremia, suggested no
major publication bias (Kendall tau 0.02; p = 0.82).
When all 81 studies were considered, hyponatremia was
significantly associated with an increased risk of overall mortality
(RR = 2.60[2.31–2.93]; p,0.0001). Similar results were obtained
when patients with specific diseases or series of hospitalized
patients were analyzed separately (Figure 2, panels A–E). Similar
to what observed for mortality rate, the Begg-adjusted rank
correlation test, calculated on the basis of mean serum [Na+]
between subjects who eventually died when compared to
survivors, suggested no major publication bias (Kendall tau
20.145; p = 0.553). The baseline mean difference of serum
[Na+] was significantly lower in subjects who eventually died
when compared to survivors (130.165.6 vs 134.965.1 mmol/L) at
follow up (Figure 3). Similar results were observed when studies
enrolling less than 100 subjects were excluded from the analysis
(mean difference in serum [Na+] between survivors vs dead
3.04[1.81–4.27], p,0.0001). Sub-analysis for mean serum [Na+]
in specific diseases was not performed due to insufficient data.
A meta-regression analysis showed that the hyponatremia-
related risk of overall mortality was inversely correlated with the
serum [Na+] threshold considered for each report (Figure 4).
Hence, the lower threshold considered, the higher the risk of
mortality. The latter association was confirmed in a multiple
regression model, adjusting for age, gender and diabetes mellitus
(adj. r =20.278; p,0.0001).
Hyponatremia and Mortality
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Sensitivity analyses performed considering only larger studies
(including $1000 subjects), those reporting the prevalence of
diabetes mellitus or those with severe hyponatremia ([Na+]
#125 mmol/l), confirmed the association between hyponatremia
and mortality (RR = 2.521[2.180–2.916]; p,0.0001 and
2.886[2.228–3.737], 10.036[5.155–19.540]; all p,0.0001, respec-
tively).
Discussion
Hyponatremia has been associated with increased in-hospital
mortality [11], but no published comprehensive meta-analysis
that analyzed the mortality rate in subjects with or without
hyponatremia had been performed to date. Very recently, the
Meta-Analysis Global Group in Chronic heart failure (MAG-
GIC) published a meta-analysis that included 14766 patients
from 22 studies that recruited patients with HF and reported
death from any cause [19]. Patients with hyponatremia
(n = 1618) had an increased risk of death (21%), compared to
patients with normal serum [Na+] (16%), and the risk of death
appeared to increase linearly with serum [Na+] ,140 mmol/L.
Hyponatremia was an independent predictor of death either
when the patients were considered as a whole, or when they
were grouped based on the presence of a reduced (n = 1199) or a
preserved (n = 419) ejection fraction. The MAGGIC meta-
analysis was limited to patients with HF and considered studies
published to the end of 2008.
Our meta-analysis included all of the English-language
published studies up until October 1st 2012 that compared the
mortality rate in human subjects with or without hyponatremia of
any degree. Eighty-one published studies were selected according
to specified inclusion criteria for a total of 850222 patients, of
whom 17.4% were hyponatremic. This percentage is in general
agreement with epidemiological data about the prevalence of
hyponatremia among hospitalized patients [2]. Of note, hypona-
tremia was associated with a significantly increased risk of overall
mortality when all studies were considered (RR = 2.60 [2.31–
2.93]). A detailed analysis of cause specific mortality was not
possible, because this information was not available in several
studies, as also was found in the MAGGIC meta-analysis.
Nevertheless, we were able to conclude that the risk of mortality
was independent of factors including age, gender, and diabetes
mellitus as an associated morbidity. Similarly, hyponatremia was
found to be associated with an increased risk of death when the
patients were analyzed separately based on different disease types
or when sensitivity analysis was restricted to larger studies or those
reporting the prevalence of diabetes. In particular, we were able to
confirm the data of the MAGGIC meta-analysis on hyponatremic
patients with HF (RR = 2.47 [2.09–2.92]), analyzing a greater
number of patients (168971, of whom 20.4% were hyponatremic).
Figure 1. Trial flow diagram.
doi:10.1371/journal.pone.0080451.g001
Hyponatremia and Mortality
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e80451
T
a
b
le
1
.
St
u
d
ie
s
in
cl
u
d
e
d
in
m
e
ta
-a
n
al
ys
is
.
S
o
u
rc
e
T
y
p
e
o
f
d
is
e
a
se
A
g
e
M
a
le
D
M
N
a
+
cu
t-
o
ff
(m
E
q
/L
)
P
a
ti
e
n
ts
H
N
H
D
e
a
th
s
H
D
e
a
th
sN
H
N
a
+
d
e
a
th
s
(m
E
q
/L
)
N
a
+
su
rv
iv
o
rs
(y
e
a
rs
)
%
%
(n
)
(n
)
(n
)
(n
)
(n
)
(m
e
a
n
±
S
D
)
(m
E
q
/L
)
(m
e
a
n
±
S
D
)
Fl
e
ar
e
t
al
.,
1
9
7
9
[2
1
]
M
yo
ca
rd
ia
l
in
fa
rc
ti
o
n
5
7
.1
7
8
.7
N
A
1
3
5
2
3
5
8
8
1
4
7
1
9
1
0
N
A
N
A
G
o
ld
b
e
rg
e
t
al
.,
2
0
0
4
[2
2
]
M
yo
ca
rd
ia
l
in
fa
rc
ti
o
n
6
1
7
8
2
4
.2
1
3
5
1
0
4
7
3
3
9
7
0
8
6
1
4
4
N
A
N
A
G
o
ld
b
e
rg
e
t
al
.,
2
0
0
6
[2
3
]
M
yo
ca
rd
ia
l
in
fa
rc
ti
o
n
5
9
.3
8
0
.7
2
2
.6
1
3
6
9
7
8
1
0
8
8
7
0
2
6
7
8
N
A
N
A
K
lo
p
o
to
w
sk
i
e
t
al
.,
2
0
0
9
[2
4
]
M
yo
ca
rd
ia
l
in
fa
rc
ti
o
n
N
A
7
2
.5
8
.9
1
3
5
1
8
5
8
9
6
1
7
6
2
1
3
6
7
N
A
N
A
H
av
ra`
n
e
k
e
t
al
.,
2
0
1
1
[2
5
]
M
yo
ca
rd
ia
l
in
fa
rc
ti
o
n
6
4
6
6
3
3
.9
1
3
5
2
1
8
7
2
1
4
6
2
5
3
0
N
A
N
A
T
ad
a
e
t
al
.,
2
0
1
1
[2
6
]
M
yo
ca
rd
ia
l
in
fa
rc
ti
o
n
6
4
.4
8
5
4
1
.4
1
3
6
1
4
0
2
9
1
1
1
0
3
N
A
N
A
T
an
g
e
t
al
.,
2
0
1
1
[2
7
]
M
yo
ca
rd
ia
l
in
fa
rc
ti
o
n
6
3
.8
6
.8
2
.9
1
3
5
1
6
2
0
2
1
2
1
4
0
8
2
9
1
0
3
N
A
N
A
P
an
ci
ro
li
e
t
al
.,
1
9
9
0
[2
8
]
H
F
6
7
7
0
.2
1
1
.8
1
3
5
1
6
1
6
4
9
7
4
4
3
9
N
A
N
A
A
d
e
w
o
le
e
t
al
.,
1
9
9
6
[2
9
]
H
F
N
A
N
A
N
A
1
2
5
6
4
1
0
5
4
7
1
7
N
A
N
A
C
h
e
n
e
t
al
.,
2
0
0
3
[3
0
]
H
F
5
6
6
3
.2
N
A
1
2
5
2
3
4
2
7
2
0
7
2
0
3
5
N
A
N
A
V
ill
ac
o
rt
a
e
t
al
.,
2
0
0
3
[3
1
]
H
F
7
2
.5
6
3
N
A
1
3
5
1
7
0
6
1
1
0
9
3
2
3
1
N
A
N
A
G
h
e
o
rg
h
ia
d
e
e
t
al
.,
2
0
0
7
[3
2
]
H
F
N
A
N
A
N
A
1
3
5
4
0
4
5
4
7
8
8
2
3
2
5
7
2
4
7
3
1
0
4
2
N
A
N
A
G
h
e
o
rg
h
ia
d
e
e
t
al
.,
2
0
0
7
[3
3
]
H
F
5
6
.2
N
A
N
A
1
3
4
4
3
0
1
0
3
3
2
7
3
1
5
2
N
A
N
A
M
ilo
-C
o
tt
e
r
e
t
al
,
2
0
0
8
[3
4
]
H
F
7
4
.9
5
1
N
A
1
3
5
2
9
6
3
8
2
5
8
1
1
2
1
N
A
N
A
T
ri
b
o
u
ill
o
y
e
t
al
.,
2
0
0
8
[3
5
]
H
F
7
4
5
3
.8
2
5
.8
N
A
6
6
2
N
A
N
A
N
A
N
A
1
3
6
.7
6
4
.9
1
3
8
.4
6
3
.6
R
u
si
n
ar
u
e
t
al
.,
2
0
0
9
[3
6
]
H
F
7
5
.8
4
6
.6
2
6
.2
1
3
6
3
5
8
9
1
2
6
7
7
3
1
5
9
N
A
N
A
B
ar
sh
e
sh
e
t
e
t
al
.,
2
0
1
0
[3
7
]
H
F
N
A
5
5
.3
5
1
.7
1
3
6
2
3
3
6
5
3
7
1
7
9
9
5
4
7
4
N
A
N
A
D
e
W
o
lf
e
e
t
al
.,
2
0
1
0
[3
8
]
H
F
5
4
.7
6
2
.9
3
4
.1
1
3
5
3
6
4
4
8
3
1
6
8
3
1
N
A
N
A
N
o
va
ck
e
t
al
.,
2
0
1
0
[3
9
]
H
F
7
5
.6
5
2
.2
3
8
.3
1
3
6
8
2
4
6
1
7
5
5
6
4
9
1
N
A
N
A
1
3
6
.4
6
5
.3
1
3
7
.6
6
4
.5
B
al
d
as
se
ro
n
i
e
t
al
.,
2
0
1
1
[4
0
]
H
F
6
2
7
4
.4
1
1
.0
1
3
5
4
6
7
0
4
6
3
4
2
0
7
1
2
3
4
3
3
N
A
N
A
B
al
lin
g
e
t
al
.,
2
0
1
1
[4
1
]
H
F
6
8
7
3
N
A
1
3
6
3
6
4
5
6
0
2
2
8
6
3
1
4
7
4
2
9
N
A
N
A
Sh
o
rr
e
t
al
.,
2
0
1
1
[4
2
]
H
F
7
4
.7
4
6
.2
N
A
1
3
5
1
1
5
9
6
9
2
4
5
6
2
9
1
4
0
7
1
3
7
2
2
7
6
3
N
A
N
A
A
rr
o
yo
e
t
al
.,
1
9
7
6
[4
3
]
C
IR
R
H
O
SI
S
N
A
N
A
N
A
1
3
0
5
5
2
1
3
4
9
6
N
A
N
A
V
ila
e
t
al
.,
1
9
9
9
[4
4
]
C
IR
R
H
O
SI
S
4
7
.3
3
5
.2
N
A
1
3
0
4
5
2
0
2
5
7
9
N
A
N
A
B
o
rr
o
n
i
e
t
al
.,
2
0
0
0
[4
5
]
C
IR
R
H
O
SI
S
5
6
.9
7
0
.5
N
A
1
3
0
1
9
1
5
7
1
3
4
1
5
1
2
N
A
N
A
P
o
rc
e
l
e
t
al
,.
2
0
0
2
[4
6
]
C
IR
R
H
O
SI
S
6
2
.9
6
2
.1
N
A
1
3
0
7
4
5
4
2
0
3
7
5
1
2
3
.8
6
5
.6
1
2
9
6
7
.7
R
u
f
e
t
al
.,
2
0
0
5
[4
7
]
C
IR
R
H
O
SI
S
4
9
5
3
N
A
1
3
0
1
9
4
3
4
1
6
0
N
A
N
A
1
3
0
6
6
.0
1
3
6
6
5
.0
H
ac
kw
o
rt
h
e
t
al
.,
2
0
0
9
[4
8
]
C
IR
R
H
O
SI
S
5
1
7
8
N
A
1
3
0
2
1
3
9
0
1
2
3
1
0
1
0
N
A
N
A
R
ad
h
a
K
ri
sh
n
a
e
t
al
.,
2
0
0
9
[4
9
]
C
IR
R
H
O
SI
S
3
6
.3
7
0
.2
N
A
N
A
1
2
1
5
0
7
1
3
8
1
6
N
A
N
A
T
e
rg
e
t
al
.,
2
0
0
9
[5
0
]
C
IR
R
H
O
SI
S
N
A
N
A
N
A
1
3
0
8
1
2
7
5
4
1
2
7
N
A
N
A
Je
n
q
e
t
al
.,
2
0
1
0
[5
1
]
C
IR
R
H
O
SI
S
5
6
7
6
.2
N
A
1
3
5
1
2
6
6
7
5
9
4
9
3
3
N
A
N
A
Si
n
g
h
i
e
t
al
.,
1
9
9
2
[5
2
]
P
N
EU
M
O
P
A
T
H
Y
3
.1
4
N
A
N
A
1
3
5
7
2
7
3
7
1
3
5
6
2
4
1
7
N
A
N
A
Sh
ar
m
a
e
t
al
.,
1
9
9
5
[5
3
]
P
N
EU
M
O
P
A
T
H
Y
3
5
5
1
N
A
1
3
5
1
1
2
4
2
7
0
N
A
N
A
1
1
7
.6
6
5
.8
1
3
2
.6
6
7
.7
Hyponatremia and Mortality
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e80451
T
a
b
le
1
.
C
o
n
t.
S
o
u
rc
e
T
y
p
e
o
f
d
is
e
a
se
A
g
e
M
a
le
D
M
N
a
+
cu
t-
o
ff
(m
E
q
/L
)
P
a
ti
e
n
ts
H
N
H
D
e
a
th
s
H
D
e
a
th
sN
H
N
a
+
d
e
a
th
s
(m
E
q
/L
)
N
a
+
su
rv
iv
o
rs
(y
e
a
rs
)
%
%
(n
)
(n
)
(n
)
(n
)
(n
)
(m
e
a
n
±
S
D
)
(m
E
q
/L
)
(m
e
a
n
±
S
D
)
El
-E
b
ia
ry
e
t
al
.,
1
9
9
7
[5
4
]
P
N
EU
M
O
P
A
T
H
Y
5
9
.1
7
5
1
7
1
3
6
8
4
9
7
5
6
1
9
N
A
N
A
H
u
ss
ai
n
e
t
al
.,
2
0
0
4
[5
5
]
P
N
EU
M
O
P
A
T
H
Y
4
7
4
2
1
5
1
3
5
1
1
0
7
8
3
2
N
A
N
A
1
2
7
.8
6
7
.4
1
3
0
.6
6
7
.5
N
ai
r
e
t
al
.,
2
0
0
7
[5
6
]
P
N
EU
M
O
P
A
T
H
Y
7
3
.5
5
0
2
0
1
3
5
3
4
2
9
5
2
4
7
9
8
N
A
N
A
So
n
g
e
t
al
.,
2
0
0
8
[5
7
]
P
N
EU
M
O
P
A
T
H
Y
N
A
N
A
N
A
N
A
9
2
9
7
8
8
5
1
1
6
6
2
N
A
N
A
Z
ilb
e
rb
e
rg
e
t
al
.,
2
0
0
8
[1
2
]
P
N
EU
M
O
P
A
T
H
Y
6
8
.4
4
5
.2
N
A
1
3
5
7
9
6
5
6
4
9
7
3
1
6
3
5
2
9
3
N
A
N
A
Su
n
d
e
ra
m
e
t
al
.,
1
9
8
3
[5
8
]
A
G
ED
N
A
0
N
A
1
3
0
6
8
3
1
0
8
5
7
5
5
3
1
0
4
N
A
N
A
Sa
m
ad
i
e
t
al
.,
1
9
8
5
[5
9
]
C
H
R
O
N
IC
D
IA
R
R
H
EA
,
3
N
A
N
A
1
3
0
1
3
3
0
2
7
6
1
0
5
4
2
8
3
8
N
A
N
A
C
u
sa
n
o
e
t
al
.,
1
9
9
0
[6
0
]
A
ID
S
3
6
.6
8
9
N
A
1
3
0
9
6
3
0
6
6
2
1
2
4
N
A
N
A
V
it
ti
n
g
e
t.
,
1
9
9
0
[6
1
]
A
ID
S
3
9
.8
9
8
N
A
1
3
2
4
8
3
4
1
4
8
2
1
2
8
6
2
1
3
3
6
1
Er
in
o
so
e
t
al
.,
1
9
9
3
[6
2
]
M
A
LN
U
T
R
IT
IO
N
,
5
5
9
.3
N
A
1
3
0
1
2
0
8
5
3
5
4
0
6
N
A
N
A
T
an
g
e
t
al
.,
1
9
9
3
[6
3
]
A
ID
S
3
4
.2
N
A
N
A
1
3
5
2
1
0
8
3
1
2
7
3
0
2
5
N
A
N
A
T
e
rz
ia
n
e
t
al
.,
1
9
9
4
[1
6
]
A
G
ED
.
6
5
4
3
.4
N
A
1
3
0
4
1
2
3
1
4
5
3
9
7
8
2
3
3
1
6
N
A
N
A
C
h
u
ah
e
t
al
.,
1
9
9
6
[6
4
]
A
M
EB
IA
SI
S
N
A
8
0
N
A
1
3
5
6
0
2
3
3
7
1
5
1
N
A
N
A
Is
e
ki
e
t
al
.,
1
9
9
6
[6
5
]
D
IA
LY
SI
S
5
0
.9
5
6
.6
N
A
N
A
1
4
9
1
N
A
N
A
N
A
N
A
1
3
4
.9
6
7
.6
1
3
6
.8
6
5
.8
Sr
iv
as
ta
va
e
t
al
.,
1
9
9
8
[6
6
]
FU
LM
IN
A
N
T
H
EP
A
T
IT
IS
5
.3
6
8
.3
N
A
1
2
5
4
1
3
3
8
3
2
2
N
A
N
A
B
e
rg
h
m
an
s
e
t
al
.,
2
0
0
0
[6
7
]
T
U
M
O
U
R
S
N
A
N
A
N
A
1
3
0
3
3
0
6
1
0
6
3
2
0
0
2
1
2
0
2
N
A
N
A
M
an
ar
y
e
t
al
.,
2
0
0
0
[6
8
]
M
A
LN
U
T
R
IT
IO
N
2
.7
4
5
.3
N
A
N
A
7
5
N
A
N
A
N
A
N
A
1
3
1
1
3
2
O
g
u
ch
e
e
t
al
.,
2
0
0
2
[6
9
]
M
A
LA
R
IA
3
4
4
N
A
N
A
5
0
8
4
2
1
1
0
N
A
N
A
A
g
ar
w
al
e
t
al
.,
2
0
0
4
[7
0
]
A
C
U
T
E
R
EN
A
L
FA
IL
U
R
E
,
1
2
7
0
N
A
N
A
5
4
1
2
4
2
9
1
9
N
A
N
A
Le
e
e
t
al
.,
2
0
0
5
[7
1
]
B
O
N
E
M
A
R
R
O
W
T
R
A
N
SP
LA
N
T
A
T
IO
N
3
2
5
8
.2
N
A
1
3
4
3
1
1
1
8
5
1
2
6
1
2
3
4
3
N
A
N
A
Sh
e
rl
o
ck
e
t
al
.,
2
0
0
6
[7
2
]
SU
B
A
R
A
C
H
N
O
ID
H
EM
O
R
R
H
A
G
E
N
A
N
A
N
A
1
3
6
3
1
6
1
7
9
1
3
7
1
9
2
6
N
A
N
A
B
o
n
n
e
y
e
t
al
.,
2
0
0
8
[7
3
]
LI
V
ER
T
R
A
N
SP
LA
N
T
A
T
IO
N
5
2
.8
4
9
.1
N
A
N
A
5
4
1
7
3
7
5
5
N
A
N
A
Fo
rf
ia
e
t
al
.,
2
0
0
8
[7
4
]
LU
N
G
H
Y
P
ER
T
EN
SI
O
N
5
5
.3
1
7
N
A
1
3
6
4
0
1
3
2
7
5
1
1
N
A
N
A
O
lo
tu
e
t
al
.,
2
0
0
8
[7
5
]
H
EM
O
LY
T
IC
-U
R
EM
IC
SY
N
D
R
O
M
E
N
A
6
1
N
A
1
2
0
3
1
8
2
3
7
1
0
N
A
N
A
H
an
so
n
e
t
al
.,
2
0
0
9
[7
6
]
M
A
LA
R
IA
3
5
7
9
.5
N
A
1
3
5
1
6
8
9
8
7
0
3
1
3
6
N
A
N
A
H
su
e
t
al
.,
2
0
0
9
[7
7
]
T
U
M
O
U
R
LI
SY
S
SY
N
D
R
O
M
E
5
5
.2
6
6
.7
N
A
N
A
1
2
N
A
N
A
N
A
N
A
1
3
2
6
6
1
4
2
6
3
K
ap
o
o
r
e
t
al
.,
2
0
1
0
[7
8
]
P
Y
EL
O
N
EP
H
R
IT
IS
5
7
1
5
.4
N
A
1
2
0
3
9
1
5
2
4
5
0
N
A
N
A
D
im
o
p
o
u
lo
s
e
t
al
.,
2
0
1
0
[7
9
]
C
O
N
G
EN
IT
A
L
H
EA
R
T
D
IS
EA
SE
3
6
.2
4
8
.7
N
A
1
3
6
1
0
0
4
1
5
6
8
4
8
3
5
6
1
N
A
N
A
Sa
lv
ad
o
r
e
t
al
.,
2
0
1
0
[8
0
]
N
EC
R
O
T
IZ
IN
G
FA
SC
IIT
IS
N
A
N
A
2
2
1
3
5
6
7
1
4
5
3
5
3
6
1
8
N
A
N
A
Sc
h
e
rz
e
t
al
.,
2
0
1
0
[8
1
]
P
U
LM
O
N
A
R
Y
EM
B
O
LI
SM
6
7
4
0
.2
N
A
1
3
5
1
3
7
2
8
2
9
0
7
1
0
8
2
1
4
4
1
8
6
6
N
A
N
A
St
e
lf
o
x
e
t
al
.,
2
0
1
0
[8
2
]
H
EA
R
T
SU
R
G
ER
Y
6
5
.4
7
6
.4
4
1
.9
1
3
3
6
7
2
7
7
8
5
5
9
4
2
8
2
1
2
4
N
A
N
A
H
o
o
rn
e
t
al
.,
2
0
1
1
[8
3
]
A
G
ED
7
0
.3
3
8
.5
1
1
1
3
6
5
2
0
8
3
9
9
4
8
0
9
2
0
6
1
5
6
7
N
A
N
A
Sa
if
u
d
h
e
e
n
e
t
al
.,
2
0
1
1
[8
4
]
G
U
IL
LA
IN
B
A
R
R
E
SY
N
D
R
O
M
E
4
2
7
2
N
A
1
3
5
5
0
2
4
2
6
4
0
N
A
N
A
Hyponatremia and Mortality
PLOS ONE | www.plosone.org 5 December 2013 | Volume 8 | Issue 12 | e80451
T
a
b
le
1
.
C
o
n
t.
S
o
u
rc
e
T
y
p
e
o
f
d
is
e
a
se
A
g
e
M
a
le
D
M
N
a
+
cu
t-
o
ff
(m
E
q
/L
)
P
a
ti
e
n
ts
H
N
H
D
e
a
th
s
H
D
e
a
th
sN
H
N
a
+
d
e
a
th
s
(m
E
q
/L
)
N
a
+
su
rv
iv
o
rs
(y
e
a
rs
)
%
%
(n
)
(n
)
(n
)
(n
)
(n
)
(m
e
a
n
±
S
D
)
(m
E
q
/L
)
(m
e
a
n
±
S
D
)
V
aa
e
t
al
.,
2
0
1
1
[8
5
]
A
LC
O
H
O
LI
C
H
EP
A
T
IT
IS
5
1
.1
8
5
N
A
N
A
2
6
N
A
N
A
N
A
N
A
1
3
2
1
3
6
T
ie
rn
e
y
e
t
al
.,
1
9
8
6
[8
6
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
6
1
.2
4
7
1
9
1
3
5
1
5
1
4
7
5
7
7
5
7
1
6
5
6
0
N
A
N
A
N
at
ku
n
am
e
t
al
.,
1
9
9
1
[8
7
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
N
A
N
A
N
A
1
2
5
1
2
1
7
2
0
2
1
0
1
5
8
4
3
5
N
A
N
A
Si
n
g
h
i
e
t
al
.,
1
9
9
4
[8
8
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
N
A
7
5
N
A
1
3
5
2
6
4
7
1
1
9
3
6
7
N
A
N
A
M
ill
e
r
e
t
al
.,
1
9
9
5
[8
9
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
6
0
–
1
0
3
9
1
.6
N
A
1
3
5
1
1
9
6
3
5
6
1
1
1
2
N
A
N
A
G
ill
e
t
al
.,
2
0
0
6
[3
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
6
5
4
7
.5
N
A
1
2
5
2
0
4
1
0
4
1
0
0
2
8
9
N
A
N
A
A
sa
d
o
lla
h
i
e
t
al
.,
2
0
0
7
[9
0
]
H
O
SP
IT
A
LI
Z
ED
SE
R
ES
N
A
N
A
N
A
1
3
4
1
5
9
9
3
5
6
1
2
4
3
1
7
9
3
7
7
N
A
N
A
St
e
lf
o
x
e
t
al
.,
2
0
0
8
[1
7
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
SE
R
IE
S
5
6
.1
5
8
.9
N
A
1
3
3
5
9
8
5
9
1
7
5
0
6
8
2
5
5
7
9
9
N
A
N
A
Z
ilb
e
rb
e
rg
e
t
al
,
2
0
0
8
[9
1
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
6
1
.8
4
5
.5
N
A
1
3
5
1
9
8
2
8
1
1
0
8
9
9
1
8
7
3
8
2
6
4
3
5
6
2
1
N
A
N
A
H
am
p
sh
ir
e
e
t
al
.,
2
0
0
9
[9
2
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
N
A
N
A
N
A
1
3
0
6
4
1
0
2
8
5
6
1
2
5
2
0
8
3
4
6
8
N
A
N
A
W
h
e
la
n
e
t
al
.,
2
0
0
9
[9
3
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
5
8
.5
4
7
.5
N
A
1
3
4
1
4
0
3
9
2
7
9
5
1
1
2
4
4
4
7
4
8
9
3
N
A
N
A
W
h
yt
e
e
t
al
.,
2
0
0
9
[9
4
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
6
8
.8
3
9
.8
N
A
1
2
0
2
2
6
1
1
3
1
1
3
2
4
7
N
A
N
A
Fu
n
k
e
t
al
.,
2
0
1
0
[9
5
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
6
3
.2
5
7
.6
N
A
1
3
5
1
4
0
9
5
2
2
6
7
8
2
1
1
4
1
7
0
4
3
6
9
1
1
0
7
4
N
A
N
A
W
al
d
e
t
al
.,
2
0
1
0
[1
1
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
6
5
.3
4
8
.2
1
4
.9
1
3
8
3
4
7
6
1
1
3
2
7
4
2
1
4
8
7
4
5
1
4
3
0
N
A
N
A
C
h
aw
la
e
t
al
.,
2
0
1
1
[1
8
]
H
O
SP
IT
A
LI
Z
ED
SE
R
IE
S
N
A
N
A
N
A
1
3
5
2
0
9
8
3
9
4
5
6
9
3
1
6
4
1
4
6
2
7
8
7
3
7
7
5
N
A
N
A
H
:
p
at
ie
n
ts
w
it
h
h
yp
o
n
at
re
m
ia
;
N
H
:
p
at
ie
n
ts
w
it
h
o
u
t
h
yp
o
n
at
re
m
ia
;
D
M
:
d
ia
b
e
te
s
m
e
lli
tu
s;
N
A
:
n
o
t
av
ai
la
b
le
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
0
8
0
4
5
1
.t
0
0
1
Hyponatremia and Mortality
PLOS ONE | www.plosone.org 6 December 2013 | Volume 8 | Issue 12 | e80451
In the MAGGIC meta-analysis, only 11% of patients were
hyponatremic, which is below the prevalence of hyponatremia
generally reported for hospitalized patients (15–30%) [2]; the
authors suggested that this might be due to the fact that all patients
in the MAGGIC cohort were outpatients at the time of the
baseline data. In contrast with the MAGGIC meta-analysis,
Figure 2. Odds ratio for overall mortality in patients with or without (no) hyponatremia according to the presence of myocardial
infarction (A), heart failure (B), cirrhosis (C), pulmonary infection (D), mixed disease (E), or in hospitalized series of subjects (F).
doi:10.1371/journal.pone.0080451.g002
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patients with hyponatremia in our meta-analysis were neither
older, nor more frequently affected by diabetes mellitus. Further-
more, we found an increased risk of mortality in hyponatremic
patients with myocardial infarction (total number of patients 6096,
of whom 18.3% with hyponatremia), cirrhosis (total number of
patients 906, of whom 42.6% were hyponatremic), or pulmonary
infections (total number of patients 10047, of whom 12% were
hyponatremic). Some studies (n = 26) reported data regarding
other mixed diseases or subpopulations (e.g., elderly people), which
could not be grouped together. The most represented diseases
Figure 3. Weighted differences (with 95% CI) of mean serum [Na+] in dead and alive patients.
doi:10.1371/journal.pone.0080451.g003
Figure 4. Relation between serum [Na+] cut-off definition and overall mortality risk.
doi:10.1371/journal.pone.0080451.g004
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among these patients (total number of patients 37864, of whom
15.1% were hyponatremic) were AIDS, malaria and malnutrition.
Finally, some studies (n = 14, total number of patients 615410, of
whom 16.7% were hyponatremic) were considered separately,
because the effect of hyponatremia on mortality was investigated
retrospectively and the diagnoses were not specified. The meta-
analysis of these studies also revealed an increased risk of overall
mortality.
The major finding of this meta-analysis is that across all groups
of patients the relative risk of mortality in patients with
hyponatremia vs patients without hyponatremia ranged between
2.47 and 3.34, thus indicating that this electrolyte disorder strongly
predicts prognosis of all hospitalized patients. Another interesting
result of our meta-analysis is that a moderate serum [Na+]
reduction (i.e., 4.8 mmol/L) was associated with an increased risk
of mortality, and a meta-regression analysis showed that the
hyponatremia-related risk of overall mortality was inversely
correlated with the serum [Na+]. Hence, the lower threshold
considered, the higher the risk of mortality. This association was
confirmed in a multiple regression model after adjusting for age,
gender and diabetes mellitus. The linear increase of risk of death
that we showed in our analysis is in agreement with the findings of
the MAGGIC meta-analysis, which found a linear increase of
mortality starting at serum [Na+] ,140 mmol/L. Overall, our
findings indicate that even a moderate reduction of serum [Na+] is
associated with an increased risk of mortality in patients affected
by multiple disease types across large numbers of hospitalized
patients.
Although the present meta-analysis both confirms and extends
the strong association between hyponatremia and adverse
outcomes such as inpatient mortality, it cannot prove a causal
relation between these variables. In fact, only diabetes mellitus
could be used as a possible confounder in the present study.
Perhaps the major outstanding question regarding hyponatremia
is whether hyponatremia contributes directly to poor outcomes or
is simply a marker for severity of underlying co-morbidities, or
possibly for other factors that might influence the progression of
underling co-morbidities [96]. Hence, it should be recognized that
potential unmeasured confounders such as other chronic diseases,
in addition to diabetes mellitus, may have caused residual
confounding, but the measured factors that are correlated with
such confounders would have mitigated the bias. Few studies to
date have attempted to address the issue of a direct effect of
hyponatremia on mortality or other adverse outcomes. One oft-
cited potential exception is the Efficacy of Vasopressin Antagonism
in Heart Failure Outcome Study with Tolvaptan (EVEREST)
study of patients with congestive heart failure, which failed to show
improvements in cardiovascular outcomes in patients with acute
heart failure (AHF) treated with the vasopressin type 2 receptor
(V2R) antagonist, tolvaptan, versus placebo [97]. However, that
study was not powered to examine outcomes in the smaller
subgroup of patients enrolled with both heart failure and
hyponatremia. More recently, a significant strong positive
relationship between an increase in serum sodium and decreased
mortality was noted in 322 patients hospitalized for AHF and
followed for 1–3 years [98]. In contrast, a multicenter analysis of
2888 patients hospitalized for AHF in Korea confirmed that
hyponatremia on admission was associated with a worse prognosis
compared with normonatremia, but this relation persisted
regardless of whether the hyponatremia improved during the
hospitalization [99]. However, this report was a retrospective
anaylsis from a registry, not a prospective randomized trial, and
the assessment of the change in serum sodium was made only
once, prior to or at discharge from the hospital [100]. Thus,
whether hyponatremia is merely a marker or also a mediator of
adverse patient outcomes is still uncertain in heart failure, and has
not been studied in other diseases. The current meta-analysis adds
further urgency to the need to answer this question for multiple
diseases, not only heart failure.
In conclusion, this study represents the first extensive and
updated meta-analysis demonstrating that hyponatremia is signif-
icantly associated with an increased risk of overall mortality, and
that it is a negative prognostic factor across multiple commonly
observed clinical conditions, such as myocardial infarction, HF,
cirrhosis and pulmonary infections. These findings might suggest
the importance to correct this electrolyte disorder, even when
mild, using the most appropriate strategies [101–103]. However,
our study did not specifically address this issue and this hypothesis
at present highlights the need for additional studies of clinical
outcomes with effective therapies in all hyponatremic patients.
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